6CM
BDTX icon

683 Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

683 Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$528K Hold
247,958
– – 0.03% 178
2025
Q4 		$603K Buy
+247,958
New +$878K 0.03% 181
2024
Q1 		– Sell
-70,379
Closed -$198K – 154
2023
Q4 		$198K Buy
+70,379
New +$165K 0.02% 203

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

683 Capital Management's BDTX Position: Q1 2026 in Review

683 Capital Management held its Black Diamond Therapeutics (BDTX) position steady in Q1 2026 at 247,958 shares worth $528K. The position accounts for 0.03% of the portfolio, ranked #178.

683 Capital Management first reported a position in BDTX in Q4 2023 and has held it in 3 quarters since. The position peaked at $603K in Q4 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • 683 Capital Management held 247,958 shares of Black Diamond Therapeutics worth $528K as of Q1 2026.
  • 683 Capital Management left its Black Diamond Therapeutics share count unchanged in Q1 2026.
  • Black Diamond Therapeutics made up 0.03% of 683 Capital Management's portfolio in Q1 2026, its #178 holding.
  • 683 Capital Management first reported a position in Black Diamond Therapeutics in Q4 2023 and has held it in 3 quarters since.
  • 683 Capital Management's Black Diamond Therapeutics position peaked at $603K in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.